○ FDA Inspections ○ Clinical Trials ✓ SEC Filings (19) ○ Press ○ EMA GMP ✓ MHRA GMP (3)

Quick Facts: ReciBioPharm

Signal Score
82.9/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Clean MHRA record: 3 compliant GMP certificates (no deductions)
Headquarters
Keele, UK · Sodertalje, SE
Modalities
AAV, Lentiviral, Plasmid, mRNA
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About ReciBioPharm

Formerly Cobra Biologics. Acquired by CRL.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Clean MHRA record: 3 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, MHRA GMDP
Clean MHRA record: 3 compliant GMP certificates (no deductions)
FDA InspectionsNo US records on file
MHRA GMP Certificates3 on record
Clean MHRA record: 3 compliant GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Charles River Laboratories
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
19 SEC filings with industry mentions on record (shown, not scored)
SEC Filings19 with industry mentions (not scored)
Parent company: Charles River Laboratories
Financial assessment: 68.0/100
Capacity 68.0
2 manufacturing sites
Broad modality coverage (4 modalities)
Sites: Keele, UK, Sodertalje, Sweden
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
2 manufacturing sites
Broad modality coverage (4 modalities)

ReciBioPharm MHRA GMP Compliance 3 certificates

2020-12
2020-12
2019-01
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA 17696 Insp GMP/IMP 17696/36548-0012[H] COBRA BIOLOGICS LIMITED KEELE ST5 5SP 2020-12-16 COMPLIANT
UK MIA(IMP) 17696 Insp GMP/IMP 17696/36548-0012[I] COBRA BIOLOGICS LIMITED KEELE ST5 5SP 2020-12-16 COMPLIANT
UK MIA(IMP) 17696 Insp IMP 17696/18644871-0001[I] COBRA BIOLOGICS LIMITED Newcastle ST5 5NT 2019-01-29 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Financial Intelligence

8-K 2026-09-24 0 keyword mentions
"Item 7.01 Regulation FD Disclosure: On September 24, 2026, in connection with its Investor Day, Charles River Laboratories International, Inc. (the “Company”) issued a press release that, among other things, discusses its business strategy, reaffirms its full-year 2026 guidance, and provides its long-term financial targets through 2030. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein."
10-Q 2026-08-05 31 keyword mentions
"crl-20260627 0001100682 12/26 2026 Q2 false P11Y 365 xbrli:shares iso4217:USD iso4217:USD xbrli:shares crl:segment xbrli:pure 0001100682 2025-12-28 2026-06-27 0001100682 2026-07-25 0001100682 us-gaap:ServiceMember 2026-03-29 2026-06-27 0001100682 us-gaap:ServiceMember 2025-03-30 2025-06-28 0001100682 us-gaap:ServiceMember 2025-12-28 2026-06-27 0001100682 us-gaap:ServiceMember 2024-12-29 2025-06-28 0001100682 us-gaap:ProductMember 2026-03-29 2026-06-27 0001100682 us-gaap:ProductMember 2025-03-30 "
"In May 2026, the Company sold the contract development and manufacturing products and services (CDMO) business, reported in the Manufacturing segment."
"Divestiture of CDMO and Cell Solutions On May 6, 2026, the Company sold its CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for net cash paid to the buyer of $ 12.4 million, net of costs to sell and subject to certain customary closing adjustments."
8-K 2026-08-05 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."
8-K 2026-05-11 0 keyword mentions
"Item 5.02 Departure of Directors or Certain Officers; Election of: Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers."
"Item 5.07 Submission of Matters to a Vote of Security Holders: At the Company’s Annual Meeting, the following proposals were"
10-Q 2026-05-07 23 keyword mentions
"crl-20260328 0001100682 12/26 2026 Q1 false P11Y 333 824 xbrli:shares iso4217:USD iso4217:USD xbrli:shares crl:segment xbrli:pure iso4217:EUR 0001100682 2025-12-28 2026-03-28 0001100682 2026-04-24 0001100682 us-gaap:ServiceMember 2025-12-28 2026-03-28 0001100682 us-gaap:ServiceMember 2024-12-29 2025-03-29 0001100682 us-gaap:ProductMember 2025-12-28 2026-03-28 0001100682 us-gaap:ProductMember 2024-12-29 2025-03-29 0001100682 2024-12-29 2025-03-29 0001100682 2026-03-28 0001100682 2025-12-27 000110"
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Divestiture of CDMO and Cell Solutions On May 6, 2026, the Company completed the sale of its CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for future contingent performance-based payments up to $ 50.0 million, subject to certain customary closing adjustments."
8-K 2026-05-07 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."
8-K 2026-02-25 7 keyword mentions
"Planned Divestiture of CDMO and Cell Solutions Businesses On February 25, 2026, Charles River Laboratories International, Inc."
"(the “Company”) announced that it has signed a definitive agreement to divest its contract development and manufacturing products and services (“CDMO”) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments."
"The CDMO business provides services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies including viral vectors and plasmid DNA; and the Cell Solutions business provides human-derived cellular materials used in the development and production of cell therapies."
10-K 2026-02-18 107 keyword mentions
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
8-K 2026-02-18 0 keyword mentions
8-K 2026-02-18 0 keyword mentions
8-K 2026-01-13 0 keyword mentions
8-K 2026-01-09 0 keyword mentions
10-Q 2025-11-05 8 keyword mentions
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the nine months ended September 27, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
10-Q 2025-08-06 8 keyword mentions
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the six months ended June 28, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
10-Q 2025-05-07 7 keyword mentions
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the three months ended March 29, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
10-K 2025-02-19 66 keyword mentions
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
10-Q 2024-11-06 5 keyword mentions
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
10-Q 2024-08-07 6 keyword mentions
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
10-Q 2024-05-09 5 keyword mentions
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About ReciBioPharm

Does ReciBioPharm hold EMA or MHRA GMP certificates?
CDMO Signal tracks 3 MHRA GMP certificates for ReciBioPharm.
What is ReciBioPharm's CDMO Signal Score?
ReciBioPharm has a Signal Score of 83/100, based on quality, operations, financial stability, and capacity data.
Evaluating ReciBioPharm for a manufacturing program?
Use the free AI matchmaker to compare ReciBioPharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Plasmid CDMOs → mRNA CDMOs →

Similar CDMOs

Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Ascend Advanced Therapies
Rockville, MD · Alachua, FL · Munich, DE
Signal Score: 78.1
AAV, Lentiviral, Plasmid
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T

Compare ReciBioPharm with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on ReciBioPharm
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.